Olivier Huillard

12PUBLICATIONS
46CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsRadiation therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 26, 2026
Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

|Jan 20, 2026
Correction: Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.

Benoit Blanchet, Alexandre Xu-Vuillard, Anne Jouinot

|Oct 30, 2024
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.

Aude Fléchon, Rafael Morales-Barrera, Thomas Powles

|Mar 27, 2024
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.

Alicja Puszkiel, Guillaume Bianconi, Blaise Pasquiers

|Jan 25, 2024
Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.

Benoit Blanchet, Alexandre Xu-Vuillard, Anne Jouinot

|Sep 19, 2023
Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and Treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated Thyroid Cancer.

David Balakirouchenane, Romain Seban, Lionel Groussin

Pageof 2

Frequent Collaborators

4 joint publications

Jérôme Clerc

2 joint publications

Gwenaelle Gravis

2 joint publications

Yohann Loriot

1 joint publications

Pascaline Boudou-Rouquette